Export your current network:
... as a vector graphic:
SVG: scalable vector graphic - can be opened and edited in Illustrator, CorelDraw, Dia, etc
... as short tabular text output:
TSV: tab separated values - can be opened in Excel and Cytoscape (lists only one-way edges: A-B)
... as tabular text output:
TSV: tab separated values - can be opened in Excel (lists reciprocal edges: A-B,B-A)
... as an XML summary:
structured XML interaction data, according to the 'PSI-MI' data standard
... protein node degrees:
node degree of proteins in your network (given the current score cut-off)
... network coordinates:
a flat-file format describing the coordinates and colors of nodes in the network
... protein sequences:
MFA: multi-fasta format - containing the aminoacid sequences in the network
... protein annotations:
a tab-delimited file describing the names, domains and descriptions of proteins in your network
... functional annotations:
a tab-delimited file containing all known functional terms of protiens in your network
Browse interactions in tabular form:
| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| ATAD1 | CYB5B | ENSSSCP00000011127 | ENSSSCP00000067019 | ATPase family AAA domain containing 1; Belongs to the AAA ATPase family. | Cytochrome b5 heme-binding domain-containing protein; Belongs to the cytochrome b5 family. | 0.412 |
| ATAD1 | MARC2 | ENSSSCP00000011127 | ENSSSCP00000011541 | ATPase family AAA domain containing 1; Belongs to the AAA ATPase family. | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | 0.513 |
| C1orf115 | MARC2 | ENSSSCP00000023310 | ENSSSCP00000011541 | Chromosome 1 open reading frame 115. | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | 0.548 |
| CYB5B | ATAD1 | ENSSSCP00000067019 | ENSSSCP00000011127 | Cytochrome b5 heme-binding domain-containing protein; Belongs to the cytochrome b5 family. | ATPase family AAA domain containing 1; Belongs to the AAA ATPase family. | 0.412 |
| CYB5B | MARC2 | ENSSSCP00000067019 | ENSSSCP00000011541 | Cytochrome b5 heme-binding domain-containing protein; Belongs to the cytochrome b5 family. | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | 0.602 |
| CYB5B | SUOX | ENSSSCP00000067019 | ENSSSCP00000000396 | Cytochrome b5 heme-binding domain-containing protein; Belongs to the cytochrome b5 family. | Sulfite oxidase, mitochondrial isoform X1. | 0.609 |
| FAR2 | MARC2 | ENSSSCP00000049639 | ENSSSCP00000011541 | Fatty acyl-CoA reductase; Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | 0.517 |
| FAR2 | NPSR1 | ENSSSCP00000049639 | ENSSSCP00000017653 | Fatty acyl-CoA reductase; Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. | Neuropeptide S receptor 1; Belongs to the G-protein coupled receptor 1 family. Vasopressin/oxytocin receptor subfamily. | 0.589 |
| FAR2 | PLD5 | ENSSSCP00000049639 | ENSSSCP00000019562 | Fatty acyl-CoA reductase; Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. | Phospholipase D family member 5. | 0.602 |
| MARC2 | ATAD1 | ENSSSCP00000011541 | ENSSSCP00000011127 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | ATPase family AAA domain containing 1; Belongs to the AAA ATPase family. | 0.513 |
| MARC2 | C1orf115 | ENSSSCP00000011541 | ENSSSCP00000023310 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Chromosome 1 open reading frame 115. | 0.548 |
| MARC2 | CYB5B | ENSSSCP00000011541 | ENSSSCP00000067019 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Cytochrome b5 heme-binding domain-containing protein; Belongs to the cytochrome b5 family. | 0.602 |
| MARC2 | FAR2 | ENSSSCP00000011541 | ENSSSCP00000049639 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Fatty acyl-CoA reductase; Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. | 0.517 |
| MARC2 | NPSR1 | ENSSSCP00000011541 | ENSSSCP00000017653 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Neuropeptide S receptor 1; Belongs to the G-protein coupled receptor 1 family. Vasopressin/oxytocin receptor subfamily. | 0.514 |
| MARC2 | PLD5 | ENSSSCP00000011541 | ENSSSCP00000019562 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Phospholipase D family member 5. | 0.515 |
| MARC2 | SNX19 | ENSSSCP00000011541 | ENSSSCP00000058120 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Sorting nexin-19 isoform X1. | 0.547 |
| MARC2 | SUOX | ENSSSCP00000011541 | ENSSSCP00000000396 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Sulfite oxidase, mitochondrial isoform X1. | 0.515 |
| MARC2 | TAPT1 | ENSSSCP00000011541 | ENSSSCP00000019996 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Transmembrane anterior posterior transformation 1. | 0.542 |
| MARC2 | TMEM97 | ENSSSCP00000011541 | ENSSSCP00000027559 | Mitochondrial amidoxime reducing component 2; Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles. As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability. May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis. Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transf [...] | Transmembrane protein 97; Intracellular orphan receptor that binds numerous drugs and which is highly expressed in various proliferating cells. Corresponds to the sigma-2 receptor, which is thought to play important role in regulating cell survival, morphology and differentiation. May play a role as a regulator of cellular cholesterol homeostasis. May function as sterol isomerase. May alter the activity of some cytochrome P450 proteins. | 0.548 |
| NPSR1 | FAR2 | ENSSSCP00000017653 | ENSSSCP00000049639 | Neuropeptide S receptor 1; Belongs to the G-protein coupled receptor 1 family. Vasopressin/oxytocin receptor subfamily. | Fatty acyl-CoA reductase; Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. | 0.589 |
page 1 of 2